Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Getinge ( ($SE:GETI.B) ) has provided an announcement.
Getinge’s Nomination Committee plans to propose seasoned healthcare executive Camilla Sylvest for election to the company’s Board of Directors at the 2026 Annual General Meeting, while long-serving board member Malin Persson has declined re-election after more than a decade of service. Sylvest’s extensive commercial and leadership experience from Novo Nordisk, including oversight of global strategy and major product launches in diabetes, obesity and cardiovascular disease, as well as her current board role at biotechnology group argenx, would strengthen Getinge’s governance with deep expertise in high-growth therapeutic areas and global market development, potentially sharpening the company’s strategic positioning in the competitive medtech and life sciences landscape.
The most recent analyst rating on ($SE:GETI.B) stock is a Hold with a SEK231.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.
More about Getinge
Getinge is a global medical technology company that supplies hospitals and life science institutions with products and solutions designed to improve clinical outcomes and optimize workflows. Its portfolio covers intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science applications, and it employs around 12,000 people with sales in more than 135 countries.
Average Trading Volume: 467,591
Technical Sentiment Signal: Buy
Current Market Cap: SEK58.26B
Learn more about GETI.B stock on TipRanks’ Stock Analysis page.